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175 Noninvasive ventilation (NIV) in cystic ﬁbrosis patients (CF) with
past pneumothorax (PNX): a case report
R. Casciaro, G. Ottonello, A. DeAlessandri, V. Emmanuele, M. Caso, M. Haupt,
L. Minicucci, L. Lorini. CF Center, Gaslini Institute, Genoa, Italy
NIV has been increasingly more applied in treatment of CF patients (pts) with severe
respiratory insufﬁciency, in particular in pts awaiting for lung transplantation (LT).
The advantages of NIV derive mainly from avoiding the complications of invasive
mechanical ventilation with tracheal prothesis. Contraindications to NIV include
past PNX in the previous 2 yrs. We describe a case of a CF patient with past PNX,
treated with NIV:
F., a 15-year-old female, had a severe respiratory insufﬁciency. She was on a trans-
plant waiting list since Oct 2005. In Nov 2005, her pCO2 value was 64.8mmHg.
She initially did not received NIV, because of a PNX occurred 6 months before.
After 6 days, because of a severe hypercapnia, we started NIV with low pressure
(Ipap 14 cm H2O, Epap 2 cm H2O, Pressure Support mode) with beneﬁt and F. was
discharged. After 3 weeks, F. was readmitted to hospital because of a left PNX.
NIV was stopped. After 9 months, F. presented dyspnoea, severe hypercapnia and
increased oxygen need. NIV was gradually reintroduced (Peep 3 cm H20, PS 16mm
H20, FiO2 0.5. Pressure Support mode) in an Intensive Care Unit (ICU), because of
the risk of PNX. NIV improved her quality and time of sleep, with partial remission
of symptoms. Blood gases did not improve. Clinical condition was critical but stable,
and F. undergo LT.
In conclusion, NIV performed in ICU and with low pressure have an important
place even in the management of FC pts with past PNX. According to literature, in
our case NIV improved respiratory symptoms and quality of sleep, without affecting
blood gases. In our patient NIV was helpful to achieve LT.
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Recurrent pneumothorax is common in CF and is associated with increased mor-
bidity and mortality. Although chemical pleurodesis and surgery are successful in
preventing recurrence in non-CF patients, there are few data regarding their efﬁcacy
in CF. To look at this, we reviewed the case records of 219 adult CF patients from
our centre since 1993 and selected those 17 (8%, 11 female) who had developed
a pneumothorax (total 35 episodes, (range 1−7). All were non-smokers with pre
pneumothorax spirometry of FEV1 (% predicted) mean 34 (17−68) and mean FVC
51 (24−76). Ten patients (59%) developed recurrence after a mean interval of
4 months (1−9) following the ﬁrst episode. The outcomes of the initial and second
line treatments are shown in the table. The highest risk of recurrence occurred
in the chest drain group (62%) followed by chemical pleurodesis (with 4 g talc)
(57%), observation (40%) and the surgical group (20%). There was one death each
in the chest drain and chemical pleurodesis group and 3 deaths occurred at a mean
11 days post surgery.
Thus, we have shown that 59% of CF patients experience a recurrent pneumothorax
within the ﬁrst year. Surgical treatment was associated with a lower risk of recur-
rence, but at the expense of an increase in mortality. Randomised controlled trials
of treatment options and the formulation of guidelines are required to determine the
timing and optimal management to prevent recurrent pneumothorax in CF patients.
Treatment Episodes of
pneumothorax
Resolution
rate
Second line
treatment
Complications Recurrence
Observation 7 5 (71%) 2 (chest drain) 0 2 (40%)
Chest drain 22 13 (59%) 8 (surgery) 1 death 8 (62%)
Chemical (talc)
pleurodesis
8 8 (100%) - 1 death 4 (57%)
Surgery 8 5 (63%) - 3 deaths 1 (20%)
177 Incidence and evolution of nasal polyposis in cystic ﬁbrosis
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Introduction: Cystic ﬁbrosis is frequently associated to nasal polyposis.
Aims: To study the incidence of nasal polyposis in children and adolescents
with cystic ﬁbrosis, its possible association to age, gender, clinical manifestations,
genotype and chlorid level, and its evolution with topical corticosteroid therapy.
Methods: Clinical symptoms (pulmonary, pancreatic insufﬁciency, undernutrition,
nasal obstruction), sweat chlorid level, genotype and nasal endoscopic ﬁndings
were studied in 23 cystic ﬁbrosis patients. Polyposis was treated with topical
corticosteroid during 6 months, followed by a second nasal endoscopy.
Results: Nasal polyposis was found in 39.1% of the patients (ﬁve bilateral, four
unilateral), recurrent pneumonia in 82.6%, pancreatic insufﬁciency in 87% and
malnutrition in 74%. No association was seen between nasal polyposis and sweat
chlorid level, genotype, clinical sings of severity and nasal symptoms. Nasal polyps
were found in children older than six years. Seven patients improved polyposis with
corticosteroid therapy, six showed complete involution.
Conclusion: The study showed a high incidence of nasal polyposis in older children,
even in the absence of clinical nasal symptoms. Patients with CF and nasal polyposis
span the entire range of clinical severity. Topical corticosteroid therapy showed good
results. An interaction among pediatricians and otolaryngologist is necessary.
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Introduction: The “Consensus Statement: Guide to Bone Health and Disease in
Cystic Fibrosis” (2004) advocates bone health assessment of patients with cystic
ﬁbrosis (CF). Subsequent scans are based on clinical need. We commenced dual
energy x-ray absorptiometry (DXA) into our annual screening programme and
report our initial experience.
Patients and Methods: Of the 162 adult patients under regular follow up,
147 (92%), 96 male, had DXA in the past 15 months. Osteopenia was deﬁned
as BMD <−1 SD to age and gender matched values (Z score) and osteoporosis
as BMD <−2 SD at the hip and lumbar spine. Spirometry, BMI, no. of infective
exacerbations in last year and vitamin D levels were assessed.
Results: 26% had osteoporosis, 33% osteopenia and 41% patients had a normal
BMD. BMI and FEV1%pred were related to both hip (r = 0.371 and r = 0.234,
p< 0.01) and spine (r = 0.331 and r = 0.317, p< 0.05) Z scores. Patients with
osteoporosis had a lower mean(SD) %pred FEV1 [53(26) versus 65(25), p< 0.001]
and an increased median no. of exacerbations (3 versus 2, p< 0.01) compared to
patients with a normal BMD. More patients with osteoporosis (45%) had a low
BMI (<20 kg/m2), c2, p< 0.001. Daily steroid dose and vitamin D levels were not
different in those with or without osteoporosis.
Conclusions: With the introduction of DXA scans into the annual assessment,
signiﬁcant bone thinning was detected, associated with a low FEV1, BMI and a
higher rate of infective exacerbations. The addition of DXA scans will improve
recognition of hidden extra pulmonary disease in patients with CF.
